• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Streamlining Transitions Between Academic and Community Centers

Opinion
Video

Jeffrey V. Matous, MD, discusses how telehealth and remote monitoring can enhance the safe administration of bispecific antibody therapies in community settings, especially for rural or underserved populations, while emphasizing the importance of communication and collaboration between academic and community practices to improve delivery and coordination of care.

Video content above is prompted by the following:

  • How can telehealth and remote monitoring, including tools for managing CRS or other toxicities, support the safe administration of bispecific antibody therapies in community settings while expanding access for rural or underserved populations?
  • How can academic and community practices strengthen communication and collaboration to support the delivery of bispecific antibody therapies, and what tools or frameworks might facilitate this coordination?
Related Videos
Dr Ameet Patel
5 experts are featured in this series
5 experts are featured in this series
Related Content
FDA approval | Image Credit: © Surendra-stock.adobe.com

FDA Green-Lights D-VRd Quadruplet for Newly Diagnosed Multiple Myeloma

January 27th 2026
Article

This approval brings the total indications for daratumumab and hyaluronidase to 5 in newly diagnosed disease and its 12th overall.

Read More

Roberto Mina, MD, Winship Cancer Institute of Emory University

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

January 23rd 2026
Article

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

Read More

Nashville | Image Credit: © f11photo-stock.adobe.com

Advancing Biomarker Testing Across GU, Lung, and Myeloma Care

January 22nd 2026
Article

Experts discuss the impact of biomarker testing on GU and lung cancers, as well as myeloma, emphasizing its role in personalized treatment and patient care advancements.

Read More

FDA | Image Credit: © Pakin-stock.adobe.com

FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval

January 21st 2026
Article

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

Read More

Teclistamab | Image Credit: ©luchschenF-stock.adobe.com

MajesTEC-9 Data Add to Accolades for Teclistamab in Multiple Myeloma

January 15th 2026
Article

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

Read More

CAR T-cell therapy

Early Data Show Promising Outcomes as CAR T-Cell Therapy Expands Beyond Academic Centers

January 12th 2026
Article

Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.